Revelation Biosciences, Inc. (NASDAQ:REVB) Stock Short Interest Rises 517.6%

Posted by Geri Gentry on Oct 10th, 2026

Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 1,581 shares, an increase of 517.6% from the September 15th total of 256 shares. Based on an average daily trading volume, of 36,220 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Revelation Biosciences Price Performance

Revelation Biosciences stock opened at $0.76 on Friday. Revelation Biosciences has a 1-year low of $0.75 and a 1-year high of $5.96. The company has a market cap of $3.02 million, a PE ratio of -0.06 and a beta of -0.07. The stock’s 50 day moving average price is $0.98 and its 200 day moving average price is $1.05.

Revelation Biosciences (NASDAQ:REVB – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. On average, equities research analysts anticipate that Revelation Biosciences will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, September 29th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Revelation Biosciences has a consensus rating of “Sell”.

Read Our Latest Stock Report on REVB

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently raised its position in Revelation Biosciences stock. Sabby Management LLC raised its stake in Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) by 192.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 605,702 shares of the company’s stock after purchasing an additional 398,651 shares during the period. Revelation Biosciences accounts for approximately 0.7% of Sabby Management LLC’s holdings, making the stock its 8th biggest holding. Sabby Management LLC owned 8.78% of Revelation Biosciences worth $484,000 at the end of the most recent reporting period. 12.80% of the stock is owned by institutional investors and hedge funds.

Revelation Biosciences Company Profile

(Get Free Report)

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.

The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.